Naslov
Financial burden of severe asthma and the impact of biologics

Autori
Peček, Mirta ; Orbanić, Ante ; Popović-Grle, Sanja

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Skup
5th Forum of Southeast European Countries on Severe Asthma

Mjesto i datum
Šibenik, Hrvatska, 09.06.2023. - 11.06.2023

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
asthma ; biologics ; costs ; financial burden ; severe asthma ; treatment

Sažetak
Introduction: Severe asthma (SA) affects 3–10% of the general asthma population and is defined as uncontrolled asthma despite adherence to maximal, optimized high-dose inhaled corticosteroid/long-acting β2-agonist therapy and management of contributing factors, or that worsens when high-dose treatment is reduced. Patients with SA experience more exacerbations and comorbidities than those with mild or moderate asthma and also have a lower quality of life. The medical burden and healthcare expenses for patients with SA are substantial. With the introduction of biologics, recent developments in the treatment of asthma have ushered in an age of potential tailored therapy for these patients. This study estimates the financial burden of SA and the accompanying expenses for biologics. Methods: The PubMed database was searched using keywords: ' ' biologics' ' , ' ' financial burden' ' , ' ' severe asthma' ' . 54 papers were found. Results: Asthma severity increases the expense of asthma annually. Comorbidities were observed to significantly increase costs for asthma patients, and even low-cost, high-prevalence disorders such as lower respiratory tract infections were considered important cost drivers. According to reports, the annual direct per patient medical cost for SA was $658 in Thailand, $135-733 in Brazil, $1277 in Spain, $1563-4369 in Turkey, $1635 in South Korea, $2214 in Korea, $3387.31 in Switzerland, $562.77 in Vietnam, $2868 in Spain, $6354 in the USA, and $8948.68 in France. In comparison to 2019, a study that anticipated the economic burden of asthma in the USA predicted that people with uncontrolled asthma will incur higher direct costs of $1056 by 2038. Direct expenditures may increase as a result of more severe instances of needing more emergency medications, routine corticosteroid use, emergency department visits, and hospitalization. Biologics are only prescribed to a limited percentage of asthma patients, despite their efficacy. However, better asthma management brought on by biologics may substantially reduce oral corticosteroids use, frequency of asthma exacerbations, emergency admissions, hospitalizations, and sick leave days. Each of the biologics costs between $879 and $4752 in wholesale purchasing costs. Careful identification of asthma patients who require biologics to achieve asthma control is crucial. Conclusion: SA has a large financial burden for both patients and society. The potential for cost savings is the use of suitable hospitalization practices, more successful ways to avoid asthma attacks, enhanced asthma control status, as well as with improved care of asthma attacks in patients with severe asthma. All biologics must reduce their costs by around 60% to 80% to be cost- effective.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti, Farmacija

POVEZANOST RADA